Spots Global Cancer Trial Database for anlotinib
Every month we try and update this database with for anlotinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL | NCT06086197 | Diffuse Large B... Diffuse Large B... | Anlotinib hydro... | 18 Years - | Zhejiang Cancer Hospital | |
| TACE Combined With Penpulimab and Anlotinib for Advanced HCC | NCT05344924 | Hepatocellular ... | TACE+penpulimab... | 18 Years - 80 Years | Zhongda Hospital | |
| A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer | NCT04914390 | Triple-negative... | AT regimen Tislelizumab Anlotinib | 18 Years - 75 Years | Sichuan Provincial People's Hospital | |
| A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC) | NCT04325763 | Stage III Non-s... | TQB2450 Anlotinib TQB2450(blank) Anlotinib(blank... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Study of Anlotinib in Patients With Primary Malignant Bone Tumors | NCT03527888 | Neoplasm of Bon... | Anlotinib | 14 Years - 70 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer | NCT05306847 | Carcinoma, Non-... | Sintilimab Anlotinib | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer. | NCT05493995 | Pancreatic Neop... | Penpulimab Anlotinib Nab paclitaxel Gemcitabine | 18 Years - | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC | NCT04507906 | NSCLC Stage IV Checkpoint Inhi... | Nivolumab Combi... | 18 Years - 75 Years | Shanghai Chest Hospital | |
| Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC | NCT03769805 | Nonsmall Cell L... | Anlotinib | 18 Years - 74 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer | NCT04803851 | Anlotinib Anti-PD-1 Antib... Advanced Pancre... | Anlotinib plus ... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas | NCT04197492 | Malignant Gliom... | Hypofractionate... Anlotinib | 18 Years - 70 Years | Huashan Hospital | |
| Anlotinib in Treatment of Recurrent Small Cell Lung Cancer | NCT03732846 | Recurrent Small... | Anlotinib | 18 Years - | Peking University Cancer Hospital & Institute | |
| Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy | NCT05990231 | Esophageal Squa... | Cadonilimab com... | 18 Years - 80 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma | NCT03991975 | Advanced Acral ... | Anlotinib TQB2450 | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Phase II Study of Anlotinib in MTC Patients | NCT01874873 | Tumor | Anlotinib | 18 Years - 70 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer | NCT05028504 | Gynecological C... | Penpulimab Anlotinib | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC | NCT06258642 | Small Cell Lung... | Irinotecan Lipo... Anlotinib | 18 Years - 75 Years | Fudan University | |
| Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC | NCT03790228 | Non-squamous Ce... | Anlotinib Combi... | 18 Years - 75 Years | Henan Cancer Hospital | |
| Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients | NCT04967079 | Non Small Cell ... | Trametinib Anlotinib | 18 Years - 75 Years | Shanghai Chest Hospital | |
| A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC) | NCT04871997 | NSCLC | 18 Years - | Tongji Hospital | ||
| Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation | NCT05778149 | Aumolertinib Anlotinib TP53 NSCLC EGFR Activating... | Aumolertinib,An... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC | NCT04895930 | Non-Small-Cell ... | Furmonertinib Anlotinib | 18 Years - 75 Years | Shanghai Chest Hospital | |
| Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC | NCT04157140 | Hepatocellular ... | Anlotinib TACE+RFA | 18 Years - 75 Years | Beijing Ditan Hospital | |
| Anlotinib and Irinotecan for Ewing Sarcoma | NCT03416517 | Ewing's Tumor M... | Anlotinib Irinotecan | 5 Years - 65 Years | Peking University People's Hospital | |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer | NCT04523272 | Advanced Renal ... | TQB2450 Anlotinib Sunitinib | 18 Years - 80 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin | NCT03671538 | Non-squamous No... | Anlotinib pemetrexed Cisplatin | 18 Years - 75 Years | The First Affiliated Hospital of Nanchang University | |
| Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer | NCT04718701 | Pancreatic Neop... Metastatic Panc... Locally Advance... | Anlotinib+Torip... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020） | NCT03755869 | Non-squamous NS... | Anlotinib | 18 Years - 75 Years | First Affiliated Hospital Xi'an Jiaotong University | |
| Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma | NCT04042597 | Effect of Drugs Quality of Life Chordoma Advanced Cancer | Anlotinib Hydro... | 18 Years - | Peking University People's Hospital | |
| A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3 | NCT03457844 | Gastroenteropan... | Anlotinib | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative | NCT03765775 | Carcinoma Non-small Cell ... Lung Neoplasm | Sintilimab Anlotinib Hydro... | 18 Years - 75 Years | First Hospital of Shijiazhuang City | |
| Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma | NCT05030077 | Urothelial Carc... Anlotinib Urogenital Neop... Cisplatin Carboplatin Gemcitabine Antineoplastic ... | Anlotinib Cisplatin Carboplatin Gemcitabine | 18 Years - 75 Years | Tianjin Medical University Second Hospital | |
| To Evaluate the Efficacy and Safety of Anrotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer | NCT06352008 | Event-free Life... | Anlotinib | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Anlotinib or Penpulimab in Combination With RAI for DTC | NCT04952493 | Thyroid Cancer | Anlotinib hydro... Sodium Iodide I... Penpulimab | 18 Years - | Peking Union Medical College Hospital | |
| A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer | NCT04203719 | Advanced Head, ... | AK105 Anlotinib | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203) | NCT02449343 | Soft Tissue Sar... | Anlotinib Placebo | 18 Years - 70 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) | NCT04271813 | Colorectal Canc... Immunotherapy Anlotinib Sintilimab Chemo-free Ther... First-line Trea... | Anlotinib plus ... | 18 Years - 75 Years | Shanghai Changzheng Hospital | |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) | NCT04405505 | Triple Negative... | TQB2450 Anlotinib Paclitaxel for ... | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC | NCT04157140 | Hepatocellular ... | Anlotinib TACE+RFA | 18 Years - 75 Years | Beijing Ditan Hospital | |
| A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas | NCT03591666 | Head and Neck C... Adenocarcinoma Recurrent Disea... Distantly Metas... | Anlotinib | 18 Years - 75 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC | NCT05021328 | NSCLC | Toripalimab Anlotinib SBRT 7Gy✖️5 QD | 18 Years - | Hubei Cancer Hospital | |
| A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC | NCT05896059 | Extensive Stage... | Tislelizumab Anlotinib | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC | NCT04797806 | Non Small Cell ... | Anlotinib Icotinib | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric or Gastro-esophageal Junction Cancer (APICAL-GE) | NCT04278222 | Gastric Cancer Gastro-oesophag... Immunotherapy Anlotinib Toripalimab | Anlotinib Plus ... | 18 Years - 75 Years | Shanghai Changzheng Hospital | |
| A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics | NCT01833923 | Advanced Cancer | anlotinib | 18 Years - 65 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC | NCT05229003 | Metastatic Colo... | Anlotinib Penpulimab Irinotecan | 18 Years - 85 Years | Fudan University | |
| Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC | NCT03799601 | NSCLC | Anlotinib Docetaxel Carboplatin | 18 Years - 75 Years | Tongji Hospital | |
| Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer | NCT05322499 | Stage IV Esopha... | Camrelizumab Irinotecan Paclitaxel Paclitaxel-albu... Docetaxel Anlotinib | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC | NCT03636685 | NSCLC Adenocarcinoma Squamous Cell C... | Anlotinib combi... Anlotinib combi... Anlotinib combi... Anlotinib combi... | 18 Years - 70 Years | ChineseAMS | |
| Study of Anlotinib in Patients With Gastric Cancer(ALTER0503) | NCT02461407 | Gastric Cancer | Anlotinib Placebo | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas | NCT04197492 | Malignant Gliom... | Hypofractionate... Anlotinib | 18 Years - 70 Years | Huashan Hospital | |
| Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer | NCT05558722 | Breast Cancer S... | Anlotinib | 18 Years - 70 Years | Xijing Hospital | |
| Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer | NCT06221462 | Carcinoma, Non-... | Sintilimab Anlotinib | 18 Years - 75 Years | Ningbo No.2 Hospital | |
| Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation | NCT05778149 | Aumolertinib Anlotinib TP53 NSCLC EGFR Activating... | Aumolertinib,An... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Anlotinib in Metastatic HER2 Negative Breast Cancer | NCT04002284 | Breast Neoplasm Antineoplastic ... Anlotinib | Anlotinib Hydro... | 18 Years - 75 Years | ChineseAMS | |
| Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma. | NCT05033587 | MGMT-Unmethylat... | Anlotinib AK105 Radiotherapy | 18 Years - 70 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy | NCT03792542 | Soft Tissue Sar... | Anlotinib | 18 Years - 70 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy | NCT06356675 | Advanced NSCLC | Tislelizumab Anlotinib | 18 Years - 75 Years | The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine | |
| Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma | NCT03728374 | Non-Small-Cell ... | Anlotinib | 65 Years - | First Affiliated Hospital of Wenzhou Medical University | |
| Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC | NCT05400070 | Sintilimab Lung Cancer Anlotinib Chemotherapy | Neoadjuvant the... | 18 Years - 72 Years | Tang-Du Hospital | |
| Anlotinib to Malignant Brainstem Glioma | NCT04668508 | Malignant Brain... Glioma | Anlotinib | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer | NCT04471480 | ESCC | TC/PD-1 inhibit... | 18 Years - 75 Years | Third Military Medical University | |
| Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer | NCT04933175 | Extensive Stage... | Fluzoparil Anlotinib | 18 Years - 75 Years | Fujian Provincial Hospital | |
| Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma | NCT03946943 | Soft Tissue Sar... Undifferentiate... | Anlotinib Toripalimab Blood Draw Tumor Specimen ... | 16 Years - | The First Hospital of Jilin University | |
| Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC | NCT04147728 | Stereotactic Bo... | Anlotinib Stereotactic Ra... | 18 Years - 80 Years | Peking University Third Hospital | |
| Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin | NCT03671538 | Non-squamous No... | Anlotinib pemetrexed Cisplatin | 18 Years - 75 Years | The First Affiliated Hospital of Nanchang University | |
| Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients | NCT03672136 | Carcinoma, Non-... | Anlotinib Concurrent Chem... | 18 Years - 75 Years | Shandong Cancer Hospital and Institute | |
| Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer | NCT04073550 | Small Cell Lung... | Anlotinib Placebos Topotecan | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma | NCT05167994 | Sarcoma,Soft Ti... Extremity Trunk Anlotinib Intensity-modul... Major Wound Com... | Anlotinib hydro... | 18 Years - | ChineseAMS | |
| Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib | NCT04004975 | Recurrent Gliob... | Anlotinib | 18 Years - 80 Years | Shandong Cancer Hospital and Institute | |
| Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer | NCT03983928 | Lung Cancer | TQB2450 Anlotinib | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC | NCT05896059 | Extensive Stage... | Tislelizumab Anlotinib | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer | NCT04718701 | Pancreatic Neop... Metastatic Panc... Locally Advance... | Anlotinib+Torip... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| To Evaluate the Efficacy and Safety of Anrotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer | NCT06352008 | Event-free Life... | Anlotinib | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| TISLELIZUMAB Combined With Anlotinib and Chemotherapy(XELOX) in the Treatment of Advanced Gastric Carcinoma | NCT04963088 | Gastric Cancer | BGB-A317 Anlotinib Oxaliplatin Capecitabine | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302） | NCT01924195 | Non-small Cell ... | Anlotinib Placebo capsule | 18 Years - 70 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma | NCT04765228 | Stage III Adult... | Pegylated lipos... Anlotinib | 14 Years - 75 Years | Fudan University | |
| Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT05816499 | NSCLC Stage IV NSCLC Stage III... NSCLC Stage III... | Cadonilimab Anlotinib Docetaxel | 18 Years - | Shanghai Chest Hospital | |
| Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients | NCT03672136 | Carcinoma, Non-... | Anlotinib Concurrent Chem... | 18 Years - 75 Years | Shandong Cancer Hospital and Institute | |
| the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer | NCT04978753 | Non-small Cell ... Brain Metastase... | Anlotinib | 18 Years - 75 Years | Sun Yat-sen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
